Engineered exosomes from different sources for cancer-targeted therapy DOI Creative Commons
Menghui Zhang,

Shengyun Hu,

Lin Liu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: March 15, 2023

Exosome is a subgroup of extracellular vesicles, which has been serving as an efficient therapeutic tool for various diseases. Engineered exosomes are the sort modified with surface decoration and internal molecules. After appropriate modification, engineered able to deliver antitumor drugs tumor sites efficiently precisely fewer treatment-related adverse effects. However, there still exist many challenges clinical translation exosomes. For instance, what sources modification strategies could endow most activity poorly understood. Additionally, how choose appropriately in different therapies another unresolved problem. In this review, we summarized characteristics exosomes, especially spatial temporal properties. concluded recent advances cancer fields, including sources, isolation technologies, strategies, labeling imaging methods Furthermore, applications were summarized, such photodynamic therapy, gene immunotherapy. Consequently, above provides researchers community latest ideas on exosome new direction drug development, prospective accelerate cancer-targeted therapy.

Language: Английский

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant DOI Creative Commons
Chang Yang, Bairong Xia,

Zhao-Cong Zhang

et al.

Frontiers in Immunology, Journal Year: 2020, Volume and Issue: 11

Published: Oct. 6, 2020

Ovarian cancer is the most lethal gynecologic malignancy. Surgery and chemotherapy are primary treatments for ovarian cancer; however, patients often succumb to recurrence with chemotherapeutic resistance within several years after initial treatment. In past two decades, immunotherapy has rapidly developed revolutionize treatment of various types cancer. Despite fact that response rates among remain modest, immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR)- TCR-engineered T cells developing. Therapeutic efficiency could be improved significantly if included as an adjuvant therapy, in combination chemotherapy, radiation anti-angiogenesis drugs, poly ADP ribose polymerase (PARPi). Newly technologies identify therapeutic targets, predict efficacy, screen potential provide neoadjuvant immunotherapy, utilize nanomedicine technology new opportunities have prolong patient survival. However, important issues may hinder efficacy such approaches, including hyperprogressive disease (HPD), immunotherapy-resistance, toxicity treatments, neurotoxicity, must taken into account addressed these therapies effective.

Language: Английский

Citations

246
Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection DOI
Jing Zhang, Chen Chen, Anning Li

et al.

Nature Nanotechnology, Journal Year: 2021, Volume and Issue: 16(5), P. 538 - 548

Published: Feb. 1, 2021

Language: Английский

Citations

230
A review of glioblastoma immunotherapy DOI

Ravi Medikonda,

Gavin P. Dunn, Maryam Rahman

et al.

Journal of Neuro-Oncology, Journal Year: 2020, Volume and Issue: 151(1), P. 41 - 53

Published: April 6, 2020

Language: Английский

Citations

229
Circulating biomarkers in patients with glioblastoma DOI Creative Commons
Juliana Müller Bark, Arutha Kulasinghe, Benjamin Chua

et al.

British Journal of Cancer, Journal Year: 2019, Volume and Issue: 122(3), P. 295 - 305

Published: Oct. 31, 2019

Abstract Gliomas are the most common tumours of central nervous system and aggressive form is glioblastoma (GBM). Despite advances in treatment, patient survival remains low. GBM diagnosis typically relies on imaging techniques postoperative pathological diagnosis; however, both procedures have their inherent limitations. Imaging modalities cannot differentiate tumour progression from treatment-related changes that mimic progression, known as pseudoprogression, which might lead to misinterpretation therapy response delay clinical interventions. In addition limitations, tissue biopsies invasive time be performed over course treatment evaluate ‘real-time’ dynamics. an attempt address these liquid been proposed field. Blood sampling a minimally procedure for endure could provide tumoural information guide therapy. Tumours shed content, such circulating cells, cell-free nucleic acids, proteins extracellular vesicles, into circulation, biomarkers reported cross blood–brain barrier. The use emerging field GBM. this review, we aim summarise current literature biomarkers, namely DNA vesicles potential non-invasively sampled manage patients with

Language: Английский

Citations

213
Engineered exosomes from different sources for cancer-targeted therapy DOI Creative Commons
Menghui Zhang,

Shengyun Hu,

Lin Liu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: March 15, 2023

Exosome is a subgroup of extracellular vesicles, which has been serving as an efficient therapeutic tool for various diseases. Engineered exosomes are the sort modified with surface decoration and internal molecules. After appropriate modification, engineered able to deliver antitumor drugs tumor sites efficiently precisely fewer treatment-related adverse effects. However, there still exist many challenges clinical translation exosomes. For instance, what sources modification strategies could endow most activity poorly understood. Additionally, how choose appropriately in different therapies another unresolved problem. In this review, we summarized characteristics exosomes, especially spatial temporal properties. concluded recent advances cancer fields, including sources, isolation technologies, strategies, labeling imaging methods Furthermore, applications were summarized, such photodynamic therapy, gene immunotherapy. Consequently, above provides researchers community latest ideas on exosome new direction drug development, prospective accelerate cancer-targeted therapy.

Language: Английский

Citations

198